Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.38 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.34 |
| ▸ | RELA | Q04206 | 2/20 | 0.34 |
| ▸ | TACR3 | P29371 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8244066 | 0.87 | SMN1; SMN2 (0.54) | CYP1A2CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL12362342 | 0.87 | KDM4E (0.41) | CYP1A2CYP2C19SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL313100 | 0.86 | CYP19A1 (0.40) | CYP1A2CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL15216084 | 0.86 | ACHE (0.40) | CYP1A2CYP3A4CYP2C19SMN1; SMN2KDM4E | |
| SCHEMBL3478856 | 0.85 | TACR3 (0.40) | CYP3A4SMN1; SMN2KDM4EALDH1A1CYP1A1 | |
| SCHEMBL10220208 | 0.84 | KDM4E (0.44) | CYP1A2CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL3429850 | 0.84 | SMN1; SMN2 (0.38) | CYP1A2CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL3427491 | 0.84 | KDM4E (0.45) | CYP1A2CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL12730963 | 0.82 | CYP1A1 (0.39) | CYP1A2CYP3A4CYP2C9CYP2C19SMN1; SMN2 | |
| SCHEMBL10271202 | 0.82 | KDM4E (0.44) | SMN1; SMN2KDM4EALDH1A1CYP1A1CYP1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227407-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2012-07-24 | — | — | US | disclosed |
| US-8227407-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2012-07-24 | — | — | US | disclosed |
| US-8227407-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2012-07-24 | — | — | US | disclosed |
| CN-101282978-B | Macrocylic inhibitors of hepatitis c virus | TIBOTEC PHARM LTD | 2012-07-11 | — | — | CN | disclosed |
| CN-101233147-B | Macrocyclic inhibitors of hepatitis c virus | TIBOTEC PHARM LTD | 2012-06-20 | — | — | CN | disclosed |
| EP-1912997-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-09-14 | — | — | EP | disclosed |
| EP-1912997-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2011-09-14 | — | — | EP | disclosed |
| US-8008251-B2 | Bioavailable formulations with ritonavir; potency, decreased cytotoxicity, improved pharmacokinetics; N-[18-[2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl-oxy]-2,15-dioxo- -3,14,16-triazatricyclo[14.3.0.0.sup.4,6]nonadec-7-ene-4-carbonyl]-(cyclopropyl)sulfonamide | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-30 | — | — | US | disclosed |
| US-8008251-B2 | Bioavailable formulations with ritonavir; potency, decreased cytotoxicity, improved pharmacokinetics; N-[18-[2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl-oxy]-2,15-dioxo- -3,14,16-triazatricyclo[14.3.0.0.sup.4,6]nonadec-7-ene-4-carbonyl]-(cyclopropyl)sulfonamide | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-30 | — | — | US | disclosed |
| US-8008251-B2 | Bioavailable formulations with ritonavir; potency, decreased cytotoxicity, improved pharmacokinetics; N-[18-[2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl-oxy]-2,15-dioxo- -3,14,16-triazatricyclo[14.3.0.0.sup.4,6]nonadec-7-ene-4-carbonyl]-(cyclopropyl)sulfonamide | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-30 | — | — | US | disclosed |
| US-6878722-B2 | Substituted cycloalkyl P1′ hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-6867185-B2 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| EP-1505945-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2005-02-16 | — | — | EP | disclosed |
| EP-1455809-A2 | INHIBITORS OF HEPATITIS C VIRUS | Bristol-Myers Squibb Company (US) | 2004-09-15 | — | — | EP | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004043339-A2 | SUBSTITUTED CYCLOALKYL P1' HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| US-20040038872-A1 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053349-A2 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038872-A1 | Inhibitors of hepatitis C virus | HAVCR2, LIPC, ZC3HAV1 | CYP1A2 1146/4885CYP3A4 1124/4885CYP2C9 2365/4885 |
| US-20040077551-A1 | Substituted cycloalkyl P1' hepatitis C virus inhibitors | HAVCR2, ANPEP, ENPEP | CYP1A2 3833/4885CYP3A4 2730/4885CYP2C9 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.